AVITA Medical, Inc. Q3 2025 Earnings Recap

AVITA Medical reported Q3 2025 revenues of approximately $17 million, falling short of expectations due to ongoing reimbursement disruptions, but anticipates renewed demand and adoption for its RECELL product following resolution of payment clarity.

Key Takeaways

• Revenue guidance for the full year adjusted to $70 million to $74 million, down from $76 million to $81 million.
• All seven regional Medicare Administrative Contractors have established reimbursement rates for RECELL, enhancing clinician confidence and adoption.
• The company is refining its commercial strategies, focusing on approximately 200 key burn centers, representing a $1.3 billion opportunity within the broader $3.5 billion U.S. market.
• Recent CE Mark approval for RECELL GO expands access to the technology in Europe, with the first patient treated in Germany.
• Management's immediate priorities include revitalizing order momentum, driving consistent product utilization, and finalizing the transition of the commercial organization for improved performance.